Acadia Pharmaceuticals (ACAD) Accounts Payables (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Accounts Payables of $12.2 million for Q1 2026, down 32.32% year-over-year from $18.1 million in Q1 2025, and up 12.32% quarter-over-quarter from $10.9 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Accounts Payables (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $12.2 million for Q1 2026.
- In Q1 2026, Accounts Payables fell 32.32% year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at $12.2 million (down 32.32% YoY), while the FY2025 annual figure was $10.9 million, down 32.66% from the prior year.
- Accounts Payables for Q1 2026 stood at $12.2 million, up from $10.9 million in the prior quarter.
- The five-year high for Accounts Payables was $21.7 million in Q3 2025, with the low at $10.0 million in Q3 2022.
- The 5-year median for Accounts Payables is $17.4 million (2023), against an average of $15.8 million.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 85.37% in 2022, then tumbled 32.66% in 2025.
- Acadia Pharmaceuticals' Accounts Payables stood at $12.7 million in 2022, then surged by 37.64% to $17.5 million in 2023, then retreated by 7.7% to $16.2 million in 2024, then slumped by 32.66% to $10.9 million in 2025, then climbed by 12.32% to $12.2 million in 2026.
- Business Quant data shows ACAD's Accounts Payables at $12.2 million in Q1 2026, $10.9 million in Q4 2025, and $21.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | 44.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.57 Mn |
| Mar 31, 2026 | 12.25 Mn |
| Dec 31, 2025 | 10.90 Mn |
| Sep 30, 2025 | 21.75 Mn |
| Jun 30, 2025 | 20.10 Mn |
| Mar 31, 2025 | 18.10 Mn |
| Dec 31, 2024 | 16.19 Mn |
| Sep 30, 2024 | 19.08 Mn |
| Jun 30, 2024 | 19.88 Mn |
| Mar 31, 2024 | 19.33 Mn |
| Dec 31, 2023 | 17.54 Mn |
| Sep 30, 2023 | 12.31 Mn |
| Jun 30, 2023 | 18.81 Mn |
| Mar 31, 2023 | 17.42 Mn |
| Dec 31, 2022 | 12.75 Mn |
| Sep 30, 2022 | 10.01 Mn |
| Jun 30, 2022 | 11.85 Mn |
| Mar 31, 2022 | 10.77 Mn |
| Dec 31, 2021 | 6.88 Mn |
| Sep 30, 2021 | 7.72 Mn |